» Articles » PMID: 22909282

Safety and Tolerability of Panax Ginseng Root Extract: a Randomized, Placebo-controlled, Clinical Trial in Healthy Korean Volunteers

Overview
Date 2012 Aug 23
PMID 22909282
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Panax ginseng has been extensively used as an adaptogen and is among the top 10 selling herbal supplements in the United States over the past decade. However, there have been few reports about the toxicity of P. ginseng in human studies. Given the lack of toxicological studies in human, this study investigated whether P. ginseng administration causes any noticeable toxic effects in healthy volunteers.

Methods: This study was designed as a randomized, double-blind, placebo-controlled, and parallel group trial in healthy volunteers. The subjects were required to be healthy, free from any significant disease, as assessed at screening by physical examination, medical history, and laboratory (hematological and biochemical) tests. Eligible subjects received P. ginseng extract (1 g/day or 2 g/day) or placebo over a 4-week period.

Results: Although mild adverse events, such as dyspepsia, hot flash, insomnia, and constipation, were reported in both P. ginseng and placebo group, no serious untoward reactions were reported following P. ginseng administration. Nonsignificant changes were observed in hematological and biochemical tests.

Conclusions: P. ginseng administration for 4 weeks was shown to be safe, tolerable, and free of any untoward toxic effect in healthy male and female volunteers. Future results from ongoing multicenter collaborative efforts to evaluate short- and long-term effects of P. ginseng may contribute to our current understanding of safety and tolerability of this herbal product.

Citing Articles

Preparation, optimization, and characterization of genistein-ginseng long-acting polymeric gel as a breast cancer treatment alternative.

Abdullah S, Md S, Altamimi A, Alahdal H, Ali R, Alkreathy H Discov Oncol. 2024; 15(1):257.

PMID: 38960937 PMC: 11222347. DOI: 10.1007/s12672-024-01132-8.


The Search for Drugs Derived from Natural Products for Infection Treatment in the Last 20 Years - A Systematic Review.

Marques-Santos F, Xavier Faria R, Amendoeira M Curr Top Med Chem. 2024; 24(22):1960-1999.

PMID: 38952156 DOI: 10.2174/0115680266299409240606062235.


The Effect of Ginseng Supplementation on Lipid Profile: GRADE-assessed Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.

Arabi S, Shahraki-Jazinaki M, Abadi M, Bahrami L, Chambari M, Bahari H Curr Pharm Des. 2024; 30(26):2047-2058.

PMID: 38877862 DOI: 10.2174/0113816128306300240522074056.


Phytochemicals Target Multiple Metabolic Pathways in Cancer.

Shuvalov O, Kirdeeva Y, Daks A, Fedorova O, Parfenyev S, Simon H Antioxidants (Basel). 2023; 12(11).

PMID: 38001865 PMC: 10669507. DOI: 10.3390/antiox12112012.


Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer.

Jiang R, Fang Z, Zhang H, Xu J, Zhu J, Chen K Chin Med. 2023; 18(1):125.

PMID: 37749560 PMC: 10518937. DOI: 10.1186/s13020-023-00822-9.


References
1.
Dega H, Laporte J, Frances C, Herson S, Chosidow O . Ginseng as a cause for Stevens-Johnson syndrome?. Lancet. 1996; 347(9011):1344. DOI: 10.1016/s0140-6736(96)91001-6. View

2.
Shader R, Greenblatt D . Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol. 1988; 8(4):235. View

3.
Jones B, Runikis A . Interaction of ginseng with phenelzine. J Clin Psychopharmacol. 1987; 7(3):201-2. DOI: 10.1097/00004714-198706000-00030. View

4.
Yi S, Sull J, Hong J, Linton J, Ohrr H . Association between ginseng intake and mortality: Kangwha cohort study. J Altern Complement Med. 2009; 15(8):921-8. DOI: 10.1089/acm.2008.0296. View

5.
GILLIS C . Panax ginseng pharmacology: a nitric oxide link?. Biochem Pharmacol. 1997; 54(1):1-8. DOI: 10.1016/s0006-2952(97)00193-7. View